|
Healthcare
Oppenheimer is a leading adviser to healthcare companies. We provide clients with the industry expertise and a full range of financing and advisory skills needed to grow and excel in the competitive healthcare landscape.
Our strong capabilities span the entire spectrum of financing alternatives and M&A services. Our financing capabilities include IPOs, follow-on offerings, PIPEs, registered direct offerings, convertible and debt financings and bank loans. We provide M&A services including sellside, buyside, structural defense and fairness opinions. Oppenheimer ranks fourth among underwriters for healthcare companies with a market cap under $1 billion.*
Life Sciences
Oppenheimer is dedicated to the biotechnology, generic and specialty pharmaceuticals and medical devices sub-sectors, and has built a top reputation among growing companies in this industry. Our diverse product offering allows Oppenheimer to meet the needs of all our clients, whether public or private, from research-stage biotech companies to larger specialty and generic pharmaceutical companies. Since 2000, Oppenheimer's life sciences banking team has completed approximately 330 transactions, including advising on transactions valued at approximately $8 billion and raising approximately $32 billion in financings.**
Healthcare Services
Oppenheimer's dedicated team provides support to clients across all facets of the healthcare services universe, including managed care, disease management, healthcare information technology, healthcare facilities and clinical research organizations. We have significant experience in underwriting public offerings, debt placements and bank loans, as well as serving as buyside and sellside advisor for healthcare services companies, and maintain active relationships with financial sponsors that invest in our healthcare services clients. Oppenheimer's banking professionals have advised on 124 deals since 2000, including advisory services for transactions totaling more that $6 billion and financings of more than $22 billion.**
|
